Credits Available: | 2.25 AMA PRA Category 1 Credit™ |
Patients with Fabry disease (FD) have a significantly shorter life expectancy compared to the general population, often due to cardiac or renal complications of this rare disease. There are only 2 approved therapies for FD—enzyme replacement therapy and chaperone therapy. Management of FD and its complications is a rapidly evolving field with ongoing developments; from recent guideline recommendations to new data on approved therapies to promising clinical trials on investigational therapies. Timely and proper management is essential to slow progression and avert severe complications. Clinicians who care for patients with FD will receive focused and up-to-date education on managing this rare and complex disease. This activity will be delivered via an innovative online platform and led by faculty experts in FD using virtual small groups of learners to drive discussion and learning through assessments, self-study modules, group tasks, and live group discussions.
This innovative online platform will use virtual small groups of learners to drive discussion and learning through assessments, self-study modules, group tasks, and live group discussions.
This innovative online platform will use virtual small groups of learners to drive discussion and learning through assessments, self-study modules, group tasks, and live group discussions.
This innovative online platform will use virtual small groups of learners to drive discussion and learning through assessments, self-study modules, group tasks, and live group discussions.
This innovative online platform will use virtual small groups of learners to drive discussion and learning through assessments, self-study modules, group tasks, and live group discussions.
This innovative online platform will use virtual small groups of learners to drive discussion and learning through assessments, self-study modules, group tasks, and live group discussions.
This live discussion will include tips for creating and implementing multidisciplinary, evidence-based, and patient-specific plans for FD management; monitoring and managing cardiac and renal disease in FD patients; and understanding the therapeutic landscape for managing FD.
This live discussion review the group tasks and how the findings can apply to caring for current or future patients with FD. We will also take time to discuss any other difficult concepts relating to FD management that have been brought to light as a result of this Gather-ed experience.
This group task will focus on the management of a female patient with a recent diagnosis of Fabry disease.
This group task will focus on the management of a male patient with untreated Fabry disease.
Thank you for your interest. Currently, the curriculum is closed for enrollment but we encourage you to keep an eye out for future opportunities or alternative programs that might align with your educational goals.